OncoMatch/Clinical Trials/NCT07733830
Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
Is NCT07733830 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including Adebrelimab and Nab paclitaxel for esophageal cancer.
Treatment: Adebrelimab · Nab paclitaxel · Carboplatin — A total of 120 patients with unresectable, locally advanced esophageal squamous cell carcinoma patients will be enrolled in this study and randomly divided into two groups. Arm A: After 2 cycles of induction adebrelimab plus chemotherapy, patients will be treated with concurrent chemoradiotherapy (50.4Gy/1.8Gy/28f), and adebrelimab will maintain to PD or for a maximum of 15 cycles. Arm B: Patients will be treated with concurrent chemoradiotherapy (50.4Gy/1.8Gy/28f) and adebrelimab will maintain to PD or for a maximum of 17 cycles. This study will compare the efficacy of immunotherapy in the induction and maintenance phases of radiotherapy, optimize more precise treatment plans, and potentially further increase the survival of ESCC patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Cancer type
Esophageal Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Disease stage
Required: Stage CT1N2-3M0, CT2-4BN0-3M0, CT1-4BN0-3M1 (SUPRACLAVICULAR LYMPH NODE METASTASIS), II, III, IVB (other)
Histologically confirmed cT1N2-3M0 or cT2-4bN0-3M0 or cT1-4bN0-3M1( supraclavicular lymph node metastasis) locally advanced ESCC (8th AJCC); clinically staged as II-IVb inoperable locally advanced ESCC (including non-resectable, or with contraindications to or refusal of surgery)
Performance status
ECOG 0–1(Restricted strenuous activity)
ECOG performance status 0 or 1
Demographics
Prior therapy
Cannot have received: systemic anti-tumor therapy
Haven't received any previous systemic anti-tumor therapy (including but not limited to systemic chemotherapy, radiotherapy, molecularly targeted drug therapy, immunotherapy, biologic therapy, topical therapy and other investigational therapeutic agents)
Cannot have received: anti-PD-1 therapy
Anti-PD-1 or anti-PD-L1 antibody therapy
Cannot have received: anti-PD-L1 therapy
Anti-PD-1 or anti-PD-L1 antibody therapy
Cannot have received: chemotherapy
chemotherapy
Cannot have received: radiotherapy
radiotherapy
Cannot have received: targeted therapy
targeted therapy
Cannot have received: biologic therapy
biologic therapy
Cannot have received: topical therapy
topical therapy
Cannot have received: investigational therapeutic agent
other investigational therapeutic agents
Lab requirements
Blood counts
anc ≥1500/μl, platelet count ≥100,000/μl and hemoglobin count ≥9.0 g/dl or ≥5.6 mmol/l
Kidney function
creatinine ≤1.5× uln or measured or calculated creatinine clearance ≥60 ml/min for those with creatinine levels >1.5× uln (calculated from the cockcroft-gault formula)
Liver function
total bilirubin ≤1.5× uln and alt/ast/akp levels ≤2.5× uln and albumin ≥2.8 g/dl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07733830 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CD274?
Yes, CD274 any tested is a required biomarker for enrollment.
What disease stage is eligible?
Stage CT1N2-3M0 or CT2-4BN0-3M0 or CT1-4BN0-3M1 (SUPRACLAVICULAR LYMPH NODE METASTASIS) or II or III or IVB is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages